Оценка эффективности и безопасности 3d-терапии у пациентов с субкомпенсированным циррозом печени HCV-этиологии (генотип 1b)
Аннотация
Ключевые слова
Об авторах
П. О. БогомоловРоссия
М. В. Мациевич
Россия
А. О. Буеверов
Россия
В. Д. Безносенко
Россия
Е. В. Федосова
Россия
М. Ю. Петраченкова
Россия
С. В. Коблов
Россия
К. Ю. Кокина
Россия
О. С. Кузьмина
Россия
Н. В. Воронкова
Россия
Список литературы
1. Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., and Christensen, E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97:2886-95.
2. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio P. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112: 463-72.
3. Singal A.G., Volk M.L., Jensen D., Di Bisceglie A.M., and Schoenfeld P.S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010; 8: 280-8.
4. Thein H.H., Yi Q., Dore G.J. and Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48: 418-31.
5. Butt A.A., Yan P., Lo Re V. 3rd, Rimland D., Goetz M.B., Leaf D. et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015; 175: 178-85.
6. Davis G.L., Alter M.J., El-Serag H., Poynard T., and Jennings L.W. Aging of hepatitis C virus (HCV)infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138: 513-21.
7. Waziry R., Grebely J., Amin J., Alavi M., Hajarizadeh B., George J., Matthews GV., Law M., Dore GJ. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (20002014). J Hepatol. 2016 Aug 26. pii: S0168-8278(16)304421. doi: 10.1016/j.jhep.2016.08.010.
8. Kanwal F., Hoang T., Kramer J.R., Asch S.M., Goetz M.B., Zeringue A. et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011; 140: 1182-8.
9. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M. et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39: 389-96.
10. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007; 46:206-12.
11. Hézode C., Fontaine H., Dorival C. et al. CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132-42.
12. Ferenci P. Treatment of hepatitis C in difficult-totreat patients.Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92.
13. Feld J.J., Moreno C., Trinh R., Tam E., Bourgeois S., Horsmans Y., Elkhashab M., Bernstein D.E., Younes Z., Reindollar R.W., Larsen L., Fu B., Howieson K., Polepally A.R., Pangerl A., Shulman N.S., Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016 Feb;64(2):3017. doi: 10.1016/j.jhep.2015.10.005. Epub 2015 Oct 22.
14. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C. et al. PEARL-III Study; PEARLIV Study.ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-92.
15. Zeuzem S., Jacobson I.M., Baykal T., Marinho R.T., Poordad F., Bourlière M., Sulkowski M.S., Wedemeyer H., Tam E., Desmond P., Jensen D.M., Di Bisceglie A.M., Varunok P., Hassanein T., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/ NEJMoa1401561. Epub 2014 Apr 10.
16. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., Shiffman M.L., Wedemeyer H., Berg T., Yoshida E.M., Forns X., Lovell S.S., Da Silva-Tillmann B., Collins C.A., Campbell A.L., Podsadecki T., Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/ NEJMoa1402869. Epub 2014 Apr 11.
17. US Food and Drug Administration Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634. htm (accessed 17 April 2016). European Medicines Agency (EMA) Committee for medicinal products for human use (CHMP) assessment report. Viekirax. International non-proprietary name: ombitasvir/paritaprevir/ritonavir. Procedure No. EMEA/H/C/003839/0000. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-Public_assessment_report/human /003839/WC500183999.pdf (accessed 17 April 2016). European Medicines Agency (EMA) Committee for medicinal products for human use (CHMP) assessment report. Exviera. International non-proprietary name: dasabuvir. Procedure No. EMEA/H/C/003837/0000. Available at: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Public_assessment_report/ human/003837/WC500182235.pdf (accessed 17 April 2016).
Для цитирования:
Богомолов П.О., Мациевич М.В., Буеверов А.О., Безносенко В.Д., Федосова Е.В., Петраченкова М.Ю., Коблов С.В., Кокина К.Ю., Кузьмина О.С., Воронкова Н.В. Оценка эффективности и безопасности 3d-терапии у пациентов с субкомпенсированным циррозом печени HCV-этиологии (генотип 1b). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):41-51. https://doi.org/10.22416/1382-4376-2017-27-4-41-51
For citation:
Bogomolov P.O., Matsiyevich M.V., Buyeverov A.O., Beznosenko V.D., Fedosova Y.V., Petrachenkova M.Yu., Koblov S.V., Kokina K.Yu., Kuzmina O.S., Voronkova N.V. Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):41-51. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-41-51

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.